Immunitor signs agreement to initiate steps toward clinical development of oral TB vaccine in China

HONG KONG, HONG KONG, November 27, 2018 -- Immunitor China Ltd. (Hong Kong) announces signing a service agreement with Kun Tuo Medical Research and Development (Beijing) Co., Ltd. - China-based subsidiary of global contract research organization (CRO) – IQVIA, formerly Quintiles. The signed agreement aims to provide registration regulatory consultation before starting clinical trial and ultimately the commercialization of the first-in-class therapeutic vaccine designed to treat tuberculosis. This landmark document is a preliminary step which will lead to filing a clinical trial application with the National Medical Products Administration (NMPA, formerly CFDA) – the China government regulatory organization, which approves and monitors clinical trials in mainland China and ultimately grants marketing authorization.